 | Your browser does not display parts of our website correctly. We use the latest technology available to provide you with a high quality experience; please upgrade your browser to its latest version to view the contents properly: |
Boston Scientific Corporation (BSX) develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide.
It operates through three segments: Cardiovascular, Rhythm Management, and MedSurg.
The company offers interventional cardiology products, including drug-eluting coronary stent systems used in the treatment of coronary artery disease; coronary technology products to treat atherosclerosis; intraluminal catheter-directed ultrasound imaging catheters and systems for use in coronary arteries and heart chambers, as well as peripheral vessels; and structural heart therapy systems.
It also provides stents, balloon catheters, wires, peripheral embolization devices, and vena cava filters used to treat peripheral disease; and biliary stents, drainage catheters, and micro-puncture sets to treat, diagnose, and ease benign and malignant tumors. In addition, the company offers cardiac rhythm management devices, such as implantable cardioverter defibrillator systems to detect and treat abnormally fast heart rhythms; implantable cardiac resynchronization therapy pacemaker systems used to treat heart failure; and medical technologies to diagnose and treat rate and rhythm disorders of the heart comprising steerable radio frequency ablation catheters, intracardiac ultrasound catheters, diagnostic catheters, delivery sheaths, and other accessories.
Further, it provides products to treat diseases of the pulmonary and gastrointestinal conditions; devices to diagnose, treat, and ease pulmonary disease systems within the airway and lungs; products to treat urinary stone disease and benign prostatic hyperplasia; mid-urethral sling products, sling and graft materials, pelvic floor reconstruction kits, and suturing devices; and spinal cord stimulator systems.
Shares have formed a bullish "cup and handle" and higher share prices are expected for this stock. Note that the firm reports its results tomorrow.
52-Weeks Trading Range: $14.18 - $19.84
Entry Point: $19.74
Stop Loss: $18.75
Target Price: $21.71
BSX closed at $21.70. However, we believe shares are heading higher. If you elect to stay in the stock, raise your stop loss to $21.00 to protect your gains!
